Literature DB >> 16641459

Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.

Elisabeth J Ruijgrok1, Marcel H A M Fens, Irma A J M Bakker-Woudenberg, Els W M van Etten, Arnold G Vulto.   

Abstract

Nebulized amphotericin B (AMB) combined with intravenous AMB was studied in persistently leukopenic rats with invasive pulmonary aspergillosis. Pulmonary concentrations of AMB after aerosol treatment were substantially higher than after intravenous liposomal AMB. Nebulized liposomal AMB in addition to intravenous AMB resulted in significantly prolonged survival compared to controls.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16641459      PMCID： PMC1472188          DOI： 10.1128/AAC.50.5.1852-1854.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat.

Authors:  T Daemen; M Velinova; J Regts; M de Jager; R Kalicharan; J Donga; J J van der Want; G L Scherphof
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

Review 2.  Current and future therapy of invasive fungal infections.

Authors:  V T Andriole
Journal:  Curr Clin Top Infect Dis       Date:  1998

Review 3.  Lipid formulations of amphotericin B: recent progress and future directions.

Authors:  J W Hiemenz; T J Walsh
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

4.  Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats.

Authors:  E J Ruijgrok; A G Vulto; E W Van Etten
Journal:  J Pharm Pharmacol       Date:  2000-06       Impact factor: 3.765

5.  Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats.

Authors:  E J Ruijgrok; A G Vulto; E W Van Etten
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

6.  Disposition of aerosolized liposomal amphotericin B.

Authors:  M P Lambros; D W Bourne; S A Abbas; D L Johnson
Journal:  J Pharm Sci       Date:  1997-09       Impact factor: 3.534

7.  Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.

Authors:  A C Leenders; S de Marie; M T ten Kate; I A Bakker-Woudenberg; H A Verbrugh
Journal:  J Antimicrob Chemother       Date:  1996-08       Impact factor: 5.790

8.  Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response.

Authors:  Martin J Becker; Siem de Marie; Marcel H A M Fens; Wim C J Hop; Henri A Verbrugh; Irma A J M Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

9.  Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

10.  Pharmacokinetics of aerosol amphotericin B in rats.

Authors:  Y Niki; E M Bernard; H J Schmitt; W P Tong; F F Edwards; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191
View more
  4 in total

1.  Aerosolized Delivery of Antifungal Agents.

Authors:  Jennifer Le; Daryl S Schiller
Journal:  Curr Fungal Infect Rep       Date:  2010-04-13

2.  Addition of 17-(allylamino)-17-demethoxygeldanamycin to a suboptimal caspofungin treatment regimen in neutropenic rats with invasive pulmonary aspergillosis delays the time to death but does not enhance the overall therapeutic efficacy.

Authors:  Jeannine M Refos; Alieke G Vonk; Marian T Ten Kate; Kimberly Eadie; Henri A Verbrugh; Irma A J M Bakker-Woudenberg; Wendy W J van de Sande
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

Review 3.  Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Front Microbiol       Date:  2017-05-16       Impact factor: 5.640

Review 4.  Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Authors:  Kévin Brunet; Jean-Philippe Martellosio; Frédéric Tewes; Sandrine Marchand; Blandine Rammaert
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.